Patent licensing and technology transfer are among the most commercially significant yet legally complex dimensions of intellectual property practice in India. As the country accelerates its transformation into a global innovation hub – with rising domestic patent filings, expanding pharmaceutical and technology sectors and deepening integration into international R&D supply chains – the ability to effectively license patented inventions and transfer technology across entities has become a matter of both commercial strategy and legal precision. Yet the framework governing these transactions is layered, drawing simultaneously on the Patents Act, 1970, foreign exchange regulation, competition law and India’s obligations under international treaties. Understanding this framework in its entirety is essential for patent holders, licensees, research institutions, foreign corporations and legal practitioners operating in this space.
At its core, patent licensing is a contractual arrangement by which the owner of a patent – the licensor – grants another party – the licensee – the right to use, manufacture, sell or otherwise exploit the patented invention, in exchange for consideration, typically a royalty. The licensor retains ownership of the patent and may grant such rights exclusively or non-exclusively, for a defined territory, duration or field of use. Technology transfer is a broader concept that encompasses not only the licensing of patents but also the movement of technical knowledge, know-how, trade secrets and other proprietary information from one entity to another, often as part of a joint venture, collaborative research agreement or government-to-industry commercialisation arrangement. In the Indian context, both patent licensing and technology transfer are governed principally by the Patents Act, 1970, with significant overlay from the Foreign Exchange Management Act, 1999 and the Competition Act, 2002.
The Statutory Framework Under the Patents Act, 1970
The Patents Act, 1970, as amended in 2002 and 2005, remains the foundational statute for patent licensing in India. Chapters XVI and XVII of the Act deal specifically with the working of patents, compulsory licences, licences of right and the revocation of patents – provisions that collectively reflect India’s long-standing policy of ensuring that patent monopolies serve public interest and not merely private accumulation.
Section 68 of the Act provides that a licence under a patent is not valid unless it is in writing and registered with the Controller of Patents. This registration requirement is not a formality – an unregistered licence is ineffective against third parties, meaning that a licensee who has not registered its licence cannot enforce it in infringement proceedings or assert it against a subsequent purchaser of the patent. Section 69 applies the same registration requirement to assignments and transmissions of patents and Section 70 clarifies that a registered proprietor may assign the patent or grant licences in respect thereof. These provisions together establish the documentary and administrative infrastructure within which all patent licensing transactions in India must be conducted.
The Act does not prescribe the terms of voluntary licences in detail – parties are free to negotiate royalty rates, territorial scope, exclusivity, sublicensing rights, field of use restrictions and duration. However, Section 140 of the Act contains an important limitation: certain conditions in licence agreements are void, including conditions that require the licensee to acquire any article other than the patented article from the licensor, conditions that restrict the licensee’s freedom to use non-patented materials and conditions that prevent the licensee from challenging the validity of the patent. These restrictions reflect competition policy concerns embedded within the patent statute and must be carefully navigated in licence drafting.
Types of Patent Licences
Indian patent law and practice recognise several distinct categories of licences, each with different legal characteristics and commercial implications. A voluntary licence is the product of free negotiation between the licensor and licensee and represents the predominant mode of patent commercialisation. An exclusive licence grants the licensee the sole right to exploit the patent within a defined territory or field of use, precluding the licensor from granting the same rights to others and, depending on the agreement, from exploiting the patent independently. This model is particularly prevalent in the pharmaceutical and technology sectors, where the licensee’s investment in manufacturing or commercialisation requires certainty of exclusive return.
A non-exclusive licence, by contrast, permits the licensor to grant the same rights to multiple licensees simultaneously and to exploit the patent independently. This structure is commercially advantageous where broad dissemination of the technology maximises revenue – as is often the case in the software, semiconductor and telecommunications industries. A sub-licence is a further grant made by the licensee to a third party, typically conditional upon the licensor’s consent unless the original licence agreement expressly authorises it. Sub-licensing is a critical feature of multi-tier technology transfer structures, including those involving multinational corporations, subsidiary companies and distribution networks across jurisdictions.
Beyond these voluntary forms, the Act provides for compulsory licences – licences granted by the Controller of Patents without the patent holder’s consent – and licences of right under Section 91, which the Central Government may endorse upon a patent that is not being adequately worked in India, after which any person may obtain a licence from the Controller on terms it fixes. The compulsory licensing regime is by far the most contentious aspect of Indian patent licensing law and merits detailed examination.
Compulsory Licensing – Section 84 and the Public Interest Imperative
Section 84 of the Patents Act, 1970, empowers any person to apply to the Controller of Patents for a compulsory licence over a patent, after the expiration of three years from the date of grant, on one or more of the following grounds: that the reasonable requirements of the public with respect to the patented invention have not been satisfied; that the patented invention is not available to the public at a reasonably affordable price; or that the patented invention is not being worked in the territory of India.
Before making an application under Section 84, the applicant must demonstrate that they made efforts to obtain a voluntary licence from the patent holder on reasonable terms and conditions and that such efforts were not successful within a reasonable period – generally understood to be not less than six months. This requirement ensures that the compulsory licensing mechanism is not misused to circumvent bona fide commercial negotiations.
When adjudicating a compulsory licence application, the Controller considers a range of factors including the nature of the invention, the time elapsed since the date of grant, the measures taken by the patentee to make the invention available in India, the capacity of the applicant to adequately work the invention for the benefit of the public and whether the applicant can provide capital to deploy the patented technology at scale. Section 90 of the Act sets out the terms and conditions subject to which compulsory licences may be granted, including provisions on royalty, the non-exclusivity of the licence and restrictions on export. The royalty payable under a compulsory licence is fixed by the Controller having regard to the nature of the invention, the expenditure incurred by the patentee in making the invention and the public interest.
Bayer Corporation v. Natco Pharma Ltd. – India’s First Compulsory Licence
The most consequential application of Section 84 in Indian patent history is the grant of a compulsory licence in the matter of Bayer Corporation v. Natco Pharma Ltd., decided by the Controller of Patents in 2012 and upheld by the Intellectual Property Appellate Board (IPAB) in 2013. Bayer held a patent over Sorafenib Tosylate, sold under the brand name Nexavar, a drug used in the treatment of advanced kidney and liver cancer. The drug was priced at approximately ₹2.8 lakh per month – a price that placed it wholly beyond the reach of the vast majority of Indian patients. Natco Pharma applied for a compulsory licence arguing, first, that Bayer had failed to satisfy the reasonable requirements of the public; second, that the drug was not available at a reasonably affordable price; and third, that Bayer was importing rather than manufacturing Sorafenib in India and had therefore not worked the patent in the territory of India.
The Controller upheld all three grounds and granted the compulsory licence, directing Natco to pay Bayer a royalty of six percent of net sales. The IPAB affirmed this order, holding that working a patent in India requires domestic manufacture and not merely importation. Natco was permitted to sell Sorafenib at a price of approximately ₹8,880 per month – a fraction of Bayer’s price – making the drug accessible to a vastly wider patient population. This case established that the three grounds under Section 84 are to be examined holistically and that patent protection cannot be allowed to operate as an instrument of exclusion against the public where the patentee has failed to fulfil its obligations under the statute.
Novartis AG v. Union of India – Section 3(d) and the Limits of Patentability
While not a licensing case in the strict sense, the Supreme Court’s landmark judgment in Novartis AG v. Union of India, (2013) 6 SCC 1, is indispensable to any discussion of Indian patent law as it directly shapes the landscape within which licensing negotiations occur. Novartis sought a patent for the beta-crystalline form of Imatinib Mesylate, the active ingredient in Gleevec, a drug used for treating chronic myeloid leukaemia. The Patent Office rejected the application under Section 3(d) of the Patents Act, which provides that a new form of a known substance – including its salts, esters, polymorphs and isomers – shall not be considered a patentable invention unless it results in the enhancement of the known efficacy of that substance.
The Supreme Court upheld the rejection, ruling that Section 3(d) creates a higher patentability threshold to prevent “evergreening” – the practice of making incremental modifications to existing drugs or substances in order to extend patent monopoly beyond the period justified by genuine innovation. The Court held that Novartis had failed to demonstrate significantly enhanced therapeutic efficacy for the beta-crystalline form over the known free base of Imatinib. This ruling has had profound implications for pharmaceutical patent licensing in India, effectively defining the outer boundary of what can be the subject of a patent – and therefore of a licence – in the pharmaceutical space.
F. Hoffmann-La Roche Ltd. v. Cipla Ltd. – Public Interest and Injunctive Relief
The Delhi High Court’s decision in F. Hoffmann-La Roche Ltd. v. Cipla Ltd., (2012) 49 PTC 356 (Del), addressed the intersection of patent enforcement, licensing and public interest in the context of pharmaceutical patents. Roche held a patent over Erlotinib, sold under the brand name Tarceva, a lung cancer drug. Cipla was manufacturing and selling a generic version at a significantly lower price. Roche sought an interim injunction restraining Cipla from alleged infringement.
The Division Bench of the Delhi High Court refused to grant the injunction, applying the balance of convenience test and placing significant weight on public interest considerations. The Court held that granting an injunction would effectively price a life-saving drug out of reach for a large section of the Indian population and that this consequence carried decisive weight in the equitable calculus. The judgment affirmed that Indian courts, in patent infringement proceedings involving essential medicines, will consider public interest as a factor of independent significance – not merely as a background consideration – in determining whether injunctive relief should be granted. This decision has materially shaped the negotiating dynamics in pharmaceutical patent licensing in India, since prospective licensees know that courts may be reluctant to grant sweeping injunctions where the patented product serves a critical public health function.
Ericsson v. Intex Technologies and the FRAND Framework
A major and rapidly developing area of patent licensing in India concerns Standard Essential Patents (SEPs) – patents that are necessarily infringed by any implementation of a technical standard, such as 4G LTE, 3G UMTS, Wi-Fi or Bluetooth. Holders of SEPs are typically required by Standards Setting Organisations to commit to licensing their patents on FRAND – Fair, Reasonable and Non-Discriminatory – terms as a condition of the standard’s adoption. The FRAND obligation is designed to prevent SEP holders from leveraging their standard-essential position to extract disproportionate royalties or to refuse access to the standard altogether.
In Telefonaktiebolaget LM Ericsson v. Intex Technologies, CS(OS) 1045/2014, Ericsson brought infringement proceedings against Intex and other Indian smartphone manufacturers, alleging that they were using its SEPs relating to 2G, 3G and 4G technologies without a valid licence. Ericsson sought interim injunctions and alleged that Intex had refused to engage in bona fide FRAND licence negotiations. The Delhi High Court granted interim injunctions in favour of Ericsson and directed the defendant companies to deposit royalties into court pending final determination of FRAND terms. The Court recognised that SEP holders are entitled to enforce their patents and to receive FRAND royalties and that implementers who refuse to negotiate in good faith cannot seek to benefit from the standard without compensating the patent holder.
This litigation – which also involved Micromax, Xiaomi and other device manufacturers – represented India’s most significant engagement with the FRAND framework and established that Indian courts would robustly enforce SEP rights while also scrutinising whether the licensor had genuinely offered FRAND terms before resorting to injunctive relief.
Ericsson v. Competition Commission of India – Competition Law and Patent Licensing
The intersection of patent licensing and competition law was directly addressed in Telefonaktiebolaget LM Ericsson v. Competition Commission of India, W.P.(C) 464/2014, before the Delhi High Court. The Competition Commission of India had initiated proceedings against Ericsson on complaints by Micromax and Intex, alleging that Ericsson had abused its dominant position by charging excessive and discriminatory royalties for its SEPs and by insisting on non-disclosure agreements as a precondition to FRAND licence negotiations. Ericsson challenged the CCI’s jurisdiction, contending that patent disputes fell exclusively within the purview of the Patents Act.
The Delhi High Court held that the CCI had concurrent jurisdiction to investigate the licensing conduct of SEP holders where such conduct may amount to abuse of dominance under the Competition Act, 2002. The Court held that intellectual property rights and competition law are not mutually exclusive frameworks – the exercise of a patent right is not immune from competition law scrutiny where it takes a form that distorts market competition. This judgment introduced an important regulatory dimension to patent licensing in India: licensors operating in SEP-heavy industries must be cognisant that their licensing practices – including royalty demands, negotiation conduct and licence terms – may be subject to scrutiny by the Competition Commission, in addition to patent enforcement proceedings.
Lee Pharma Ltd. v. AstraZeneca AB – Procedural Rigour in Compulsory Licensing
Not all compulsory licence applications succeed. The Controller of Patents’ decision in Lee Pharma Ltd. v. AstraZeneca AB (2016) illustrates the substantive and procedural rigour required of applicants under Section 84. Lee Pharma applied for a compulsory licence over AstraZeneca’s patent for Saxagliptin, a drug used in the treatment of Type 2 diabetes, on the grounds that the drug was unaffordable and not adequately worked in India.
The Controller rejected the application, holding that Lee Pharma had not made adequate efforts to obtain a voluntary licence from AstraZeneca on reasonable terms before filing its compulsory licence application – a prerequisite under Section 84. The Controller further held that Lee Pharma had not demonstrated the technical and financial capacity to adequately work the patent for the benefit of the public. The decision made clear that the compulsory licensing mechanism demands genuine engagement with the patent holder prior to invoking statutory intervention and that the applicant must be capable of delivering on the public interest purposes for which the licence is sought.
Technology Transfer – Regulatory and Commercial Framework
Technology transfer in India operates within a regulatory matrix that extends beyond the Patents Act. Where technology is transferred across national borders – as is typically the case in arrangements involving foreign technology holders and Indian recipients – the Foreign Exchange Management Act, 1999 and the Reserve Bank of India’s regulations governing royalty remittances become directly relevant. Prior to 2009, royalty payments under technology transfer agreements required prior RBI approval within defined ceilings. The liberalisation of this regime in 2009 abolished the automatic route caps, allowing parties to negotiate royalty terms commercially, subject to FEMA compliance and tax obligations under the Income Tax Act, 1961 and applicable Double Taxation Avoidance Agreements.
Technology transfer agreements must also navigate the Competition Act, 2002. Section 3(5) of the Competition Act provides that the right of a person to restrain infringement of intellectual property rights shall not be restricted by the competition provisions. However, this exemption has been interpreted narrowly – the CCI and the courts have consistently held that it does not immunise unreasonable conditions in IP licensing agreements from competition scrutiny. Conditions in technology transfer agreements that tie the purchase of the technology to the acquisition of unrelated products, impose territorial restrictions on the recipient beyond what is reasonably necessary or require the recipient to grant back all improvements to the transferor on exclusive or non-reciprocal terms, are vulnerable to challenge under the Competition Act.
The drafting of a robust technology transfer agreement requires careful attention to a range of commercial and legal considerations. The scope of the rights being transferred – whether patent licences, know-how, trade secrets, software licences or some combination – must be precisely defined. Royalty structures may be fixed-fee, running royalty, milestone-based or a combination and must reflect the economic value of the technology while remaining commercially viable for the recipient. Improvement and grant-back clauses are among the most negotiated provisions: the licensor will typically seek rights over improvements developed by the licensee, while the licensee will seek to limit such obligations or ensure reciprocity. Confidentiality obligations, export control compliance – particularly where the technology has dual-use potential – and dispute resolution clauses, with international arbitration being the preferred mechanism for cross-border arrangements, complete the essential architecture of a technology transfer agreement.
Government Use, Acquisition and the National Interest
The Patents Act, 1970 reserves significant powers to the Indian State to override private patent rights in defined circumstances. Section 100 empowers the Central or State Government or a government undertaking, to use any patented invention for government purposes without the patent holder’s consent, subject to the payment of adequate remuneration. This provision is of particular significance in defence procurement and public health contexts, where government entities may need access to patented technologies on terms that preclude voluntary licensing at market rates.
Section 102 goes further, empowering the Central Government to acquire a patent outright by notification for a public purpose, upon payment of compensation as agreed with the patentee or determined by the High Court. This is an extraordinary power that has been used sparingly but remains a significant feature of India’s patent framework – one that reinforces the principle, consistently expressed throughout the Patents Act, that patent monopolies are granted subject to obligations of public service and may be overridden where the public interest so requires.
India’s Technology Transfer Ecosystem – Institutional Framework
India has built a growing institutional infrastructure to support technology transfer, particularly in the context of publicly funded research. The National IPR Policy, 2016 articulated a framework for the commercialisation of IP generated in government-funded research institutions and encouraged the establishment of Technology Transfer Offices (TTOs) at major research organisations. Institutions including the IITs, IISc Bangalore, CSIR laboratories, DRDO and ICMR have developed licensing and commercialisation capabilities that enable academic and government-generated patents to reach the market through licensing to private sector entities.
The Department for Promotion of Industry and Internal Trade (DPIIT) has also implemented facilitation mechanisms for startups seeking to license publicly held patents, including the Startup India IP Protection scheme which provides access to panel facilitators and subsidised prosecution and licensing support. For early-stage companies and research-intensive startups, these institutional channels represent a meaningful alternative to negotiating licences with large private patent holders.
Conclusion
Patent licensing and technology transfer in India operate at the confluence of intellectual property law, competition regulation, foreign exchange policy and enduring questions of public access and national development. The Patents Act, 1970 provides a sophisticated and deliberately calibrated framework – one that acknowledges the exclusive rights of patent holders while subjecting those rights to meaningful public interest obligations through compulsory licensing, government use provisions and Section 3(d)’s higher patentability threshold. The body of case law that has developed around this framework – from Bayer’s compulsory licence to the FRAND battles in the Delhi High Court – reflects an Indian patent system that is engaged, evolving and increasingly consequential on the global IP stage.
For patent holders, the imperative is to adequately work patents in India, price products accessibly where public health is at stake and approach licensing negotiations with transparency and good faith. For technology recipients and licensees, thorough due diligence, well-drafted agreements and regulatory compliance are the foundations of a secure and productive licensing relationship. And for policymakers and practitioners, the challenge remains what it has always been in Indian IP law: to hold the balance, with clarity and consistency, between innovation incentives and the public interest in access to technology.
References
- The Patents Act, 1970 – https://ipindia.gov.in
- Bayer Corporation v. Natco Pharma Ltd., Controller of Patents, 2012; IPAB, 2013 – https://ipindia.gov.in
- Novartis AG v. Union of India, (2013) 6 SCC 1 – https://main.sci.gov.in
- F. Hoffmann-La Roche Ltd. v. Cipla Ltd., (2012) 49 PTC 356 (Del) – https://delhihighcourt.nic.in
- Telefonaktiebolaget LM Ericsson v. Intex Technologies, CS(OS) 1045/2014, Delhi High Court – https://delhihighcourt.nic.in
- Telefonaktiebolaget LM Ericsson v. Competition Commission of India, W.P.(C) 464/2014 – https://delhihighcourt.nic.in
- Lee Pharma Ltd. v. AstraZeneca AB, Controller of Patents, 2016 – https://ipindia.gov.in
- TRIPS Agreement, WTO – https://www.wto.org/english/docs_e/legal_e/27-trips.pdf
- National IPR Policy, 2016, DPIIT – https://dpiit.gov.in
- Competition Act, 2002 – https://cci.gov.in
- Foreign Exchange Management Act, 1999, RBI – https://rbi.org.in